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SUMMARY
Seizures are a common manifestation of acute neurologic insults in neonates and are
often resistant to the standard antiepileptic drugs that are efficacious in children and
adults. The paucity of evidence-based treatment guidelines, coupled with a rudimen-
tary understanding of disease pathogenesis, hasmade the current treatment of neona-
tal seizures empiric and often ineffective, highlighting the need for novel therapies.
Key developmental differences in c-aminobutyric acid (GABA)ergic neurotransmis-
sion between the immature and mature brain, and trauma-induced alterations in the
function of the cation-chloride cotransporters (CCCs) NKCC1 and KCC2, probably
contribute to the poor efficacy of standard antiepileptic drugs used in the treatment of
neonatal seizures. Although CCCs are attractive drug targets, bumetanide and other
existing CCC inhibitors are suboptimal because of pharmacokinetic constraints and
lack of target specificity. Newer approaches including isoform-specific NKCC1 inhibi-
tors with increased central nervous system penetration, and direct and indirect strate-
gies to enhance KCC2-mediated neuronal chloride extrusion, might allow therapeutic
modulation of theGABAergic system for neonatal seizure treatment.
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Seizures occur more often during the neonatal period than
at any other time during life, with a reported incidence in
postindustrial societies of up to 3.5 per 1,000 live births, and
higher in preterm infants.1,2 Neonatal seizures are most
commonly caused by perinatal asphyxia, and other causes
include intracranial hemorrhage, cerebral infarction,
and central nervous system (CNS) infection, such as
meningitis.1
Neonatal seizures portend severe neurologic dysfunction
later in life, with survivors experiencing higher rates of
postneonatal epilepsy and motor and cognitive deficits.3,4
Rodent models have revealed that seizures early in
development alter synaptic organization and plasticity, and
may prime cortical neurons to increased seizure suscepti-
bility.5 Therefore, the prompt diagnosis and successful
treatment of seizures early in life is necessary for improv-
ing long-term neurologic outcomes.
Standard antiepileptic drugs (AEDs) that enhance c-amino-
butyric acid (GABA)ergic transmission by directly targeting
GABAA receptors (GABAARs), such as phenobarbital and
benzodiazepines, are less effective in suppressing seizures in
neonates than in adults.6,7 This is not surprising, because the
signaling mechanisms and pharmacologic properties of neu-
rons in the immature brain are significantly different from
those in the adult.8 It is notable that many neonatal seizures
are clinically occult, going unnoticed without electroen-
cephalography (EEG) monitoring.9 In neonates, GABAAR-
enhancing AEDs can also elicit so-called “electroclinical
uncoupling,” whereby the overt clinical manifestations of
seizures (e.g., convulsions) are inhibited, but electrographic
seizure activity is either unaffected or exacerbated.10
Clearly, new therapeutic strategies are needed.
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Recently, there has been an increasing interest in the
indirect modulation of GABAergic responses based on a
strategy of targeting the plasmalemmal ion transporters
responsible for the generation and maintenance of the ion
gradients that drive GABAAR-mediated currents.
11,12 This
approach is motivated by the fact that short-term and long-
term changes in the functional properties of ion transporters
have a major influence on GABAergic signaling during neu-
ronal maturation and following trauma and seizures in
adults and neonates (Fig. 1).11,12 GABAAR-mediated cur-
rents are driven by Cl and HCO3 electrochemical gradi-
ents in postsynaptic neurons.13 Key molecules in neuronal
homeostasis of Cl include members of the SLC12 cation-
chloride cotransporters (CCCs), especially the Na-K-2Cl
cotransporter NKCC1 and the K-Cl cotransporter
KCC2.13,14 As secondary active transporters, the CCCs
derive their energy for active transport of Cl from the
transmembrane gradients of Na+ (for NKCC1) or K+ (for
KCC2), which are generated by the plasmalemmal Na-K
ATPase. Intraneuronal regulation of HCO3 is based on sec-
ondary active acid-base transporters and carbonic anhydras-
es.13,15
During early development, neurons harbor a low func-
tional expression of the main neuron-specific Cl extruder
KCC2, and GABAARs mediate a net efflux of Cl
 ions
down an electrochemical gradient, which is generated by
Cl accumulation via NKCC1.13 This results in depolariz-
ing, and sometimes even excitatory actions of GABA,
which can trigger release of conventional neurotransmitters
and neuroactive peptides. During neuronal maturation, the
expression and functionality of KCC2 are progressively
increased, which sets the basis for the generation of classical
hyperpolarizing inhibitory postsynaptic potentials (IPS-
Ps).16 The efficacy of hyperpolarizing IPSPs is determined
by the number of open GABAARs and functionality of
CCCs, which generate the driving force (Vm  EIPSP) and
thus the polarity of GABAAR-mediated currents. For exam-
ple, experimental knockdown of KCC2 in mature cortical
principal and cerebellar Purkinje neurons abolishes the driv-
ing force for hyperpolarizing GABAAR-mediated signal-
ing.16,17 In addition to the effects on membrane potential,
opening of GABAARs increases the conductance of the tar-
Figure 1.
Hypothetical model of pharmacologic targeting of NKCC1 in post-
asphyxia neurons. NKCC1 and KCC2 are secondary active trans-
porters that, under physiological conditions, mediate neuronal Cl
uptake and extrusion, respectively. Net ion transport by NKCC1
and KCC2 is fueled by the Na+ and K+ chemical gradients gener-
ated by the Na–K ATPase. The ion stoichiometry renders NKCC1
and KCC2 electrically silent (electroneutral). (Upper panel) In
healthy cortical neurons of human neonates, Cl extrusion via
KCC2 is likely to be more efficient than uptake via NKCC1, which
promotes a postsynaptic hyperpolarizing current triggered by
GABAergic signaling. (Middle) After neuronal trauma caused by
birth asphyxia, functional up-regulation of NKCC1 takes place, and
the direction of the Cl current is reversed which leads to depo-
larizing GABA responses. Under these conditions, application of
positive modulators of GABAARs (phenobarbital, benzodiaze-
pines) can lead to aggravation of seizures promoted by the depo-
larizing if not directly excitatory Cl current. (Bottom)
Pharmacologic block of NKCC1 by bumetanide attenuates or
abolishes the depolarizing GABA response, and subsequent appli-
cation of positive modulators of GABAARs will lead to effective
shunting inhibition, which clamps the membrane potential close
to its resting level, thereby preventing action-potential generation
in the postsynaptic neuron. (For further details, see text.)
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get neuron, which has an inhibitory action by short-circuit-
ing or “shunting” of simultaneous excitatory signals.13
Blocking NKCC1 enhances the efficacy of GABA-medi-
ated shunting inhibition in neurons that would otherwise
sustain strongly depolarizing or even excitatory GABA
responses (Fig. 1).
In rodent cortical neurons, the “developmental EGABA
shift” from depolarizing to hyperpolarizing takes place
postnatally,14 and the lack of efficacy of drugs such as phe-
nobarbital in human neonates has often been attributed to
the lack of KCC2 expression in the cortical structures of the
newborn.18,19 This kind of rodent-to-human extrapolation
ignores the fact that in terms of cortical development, the
human neonate is much more advanced than the rodent,
which is born at a stage corresponding roughly to the second
half of gestation in humans.20,21 The cortical EEG of
neonatal rodents and preterm infants is discontinuous and
dominated by discrete events known as “delta brushes” or
“spontaneous activity transients”; in humans these events
disappear already at or soon after term birth.8,22 This pro-
found change in the overall properties of the human EEG is
associated with a steep prenatal increase in KCC2 expres-
sion (see also Fig. 2).23
Descriptions of the developmental expression patterns of
NKCC1 in the rodent cortex appear discrepant. Plotkin
et al.24 first reported a developmental peak in NKCC1
expression around the first postnatal week in the rat fore-
brain, with down-regulation of NKCC1 messenger RNA
(mRNA) and protein after this time point. In contrast, no
down-regulation of NKCC1 mRNA was observed in the rat
cortex by Clayton et al.26, who suggested that the loss of
NKCC1 expression observed by Plotkin et al. may actually
reflect changes in the C-terminal splicing of NKCC1. Two
ubiquitously expressed splice variants of NKCC1 have been
characterized in mouse and human.25,27 The mRNA of the
shorter of the two variants NKCC1b which is produced by
splicing out exon 21, constitutes up to ~80% of the total
NKCC1 transcript in the adult human brain.27 It is not unli-
kely that the reported “developmental down-regulation” of
NKCC1 protein in the human cortex,19 reflects the use of an
NKCC1 rabbit antibody (Chemicon International28) raised
against a 22 amino acid sequence near the C-terminus of rat
NKCC1; a sequence that is absent from human NKCC1b as
it strongly overlaps with exon 21. Use of such an antibody is
expected to result in failure of detecting the major NKCC1
splice variant in the adult brain. Indeed, in the human cortex,
no down-regulation, but rather progressive up-regulation of
NKCC1 transcripts across the entire life-span is evident
(Fig. 2).29 Such data are not, however, sufficient to yield
information about the functional expression of NKCC1, as
the subcellular expression pattern of NKCC1 determines its
physiologic actions.30 Electrophysiological work on
Figure 2.
Expression of SLC12A2 (NKCC1) and SLC12A5 (KCC2) transcripts during human brain development. Line plots show the log2-trans-
formed NKCC1 and KCC2 exon array signal intensity from the early fetal period to late adulthood. The solid line with arrow between
periods 7 and 8 separates prenatal from postnatal periods. NCX, neocortex; HIP, hippocampus; AMY, amygdala; STR, striatum; MD, me-
diodorsal nucleus of the thalamus; CBC, cerebellar cortex; PCW, postconceptional week; M, month; Y, year. Data reproduced with per-
mission from http://hbatlas.org; see Kang et al.114
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NKCC1 knockout (KO) animals has shown that this trans-
porter modulates GABAergic signaling at the axon initial
segment of adult neocortical and hippocampal principal
neurons.30 Unfortunately, the lack of specific NKCC1
antibodies has complicated the interpretation of immuno-
chemical studies on the subcellular distribution of
NKCC1.14
The low level of KCC2 activity is likely to contribute
to the poor anticonvulsant action of phenobarbital and
other GABAAR-enhancing drugs in newborn rodents, but
does not necessarily provide a robust explanation as to
why these compounds have limited efficacy in human
neonates. Two major points should be considered here.
(1) In order to maintain effective IPSPs under in vivo con-
ditions, the efficacy of Cl extrusion has to be sufficient
to keep the reversal potential of currents carried by Cl at
a level more negative than the action potential threshold
despite the large intracellular Cl loads generated by syn-
aptic transmission, especially, during seizures.31,32 In
addition to being possibly attributable to different density
and subunit composition of GABAARs, the lack of effi-
cacy of GABAAR-enhancing AEDs in the human neonate
may reflect the limited capacity (in other words, the
small physiologic “safety factor” [cf. Ref. 33]) of Cl
extrusion in immature neurons. (2) The rapid functional
up-regulation of NKCC1, shown to take place in response
to neonatal hypoxia-ischemia,34 hypoxia-induced neonatal
seizures,35 as well as hypoxic-ischemic and mechanical
cellular trauma,36,37 is bound to cause an additional cellu-
lar Cl load that would render GABAergic inhibition less
effective, if not frankly excitatory.32 Thus, in addition to
seizures, birth asphyxia, which often is accompanied by
brain injury, is already in itself likely to induce fast func-
tional up-regulation of NKCC1.
Given the therapeutic implications of the above observa-
tions and controversies, the aims of this review are to (1)
evaluate the CCCs as putative drug targets in the treatment
of neonatal seizures, with a primary but not exclusive
focus on NKCC1; (2) examine the potential therapeutic
utility of currently available CCC-targeting drugs, espe-
cially bumetanide; and (3) describe novel approaches of
targeting the CCCs that, given the limitations of bumeta-
nide, might be more efficacious modulators of Cl trans-
port in the CNS.
Cation-Chloride
Cotransporters as CNS Drug
Targets
Seven members (SLC12A1-7) of the SLC12A gene family
encode for secondary active Cl transporters. These include
the Na-Cl cotransporter NCC, the Na-K-2Cl cotransporters,
NKCC isoforms 1–2, and the K-Cl cotransporters, KCC iso-
forms 1–4.14 Of these, the expression of KCC2 is restricted
to central nervous system (CNS) neurons.16,38 While
NKCC1 is expressed ubiquitously,39 NCC and NKCC2 are
not expressed in brain tissue,12,26 and the CNS expression of
KCC1 and KCC4 is limited.14 Although widely expressed
in the CNS, the exact physiological role of KCC3 remains
unclear.14,17 Of interest, Andermann syndrome, a severe
autosomal recessive Mendelian form of peripheral neurop-
athy associated with agenesis of the corpus callosum is
caused by loss-of function mutations in KCC3,40 revealing
the necessity of this KCC isoform for both CNS and
peripheral nervous system (PNS) development. The indis-
pensability of KCC2 to CNS function is underscored by
the fact that mice with complete loss of this protein die at
birth.41
KCC2
Compared to the other mammalian KCCs, KCC2
(encoded by SLC12A5) is unique in that it is expressed
exclusively in CNS neurons. KCC2 has attracted attention
as a prime target for the pharmacologic control of neuronal
Cl concentration, and consequently GABAergic responses.
What is typically ignored, however, is that KCC2, indepen-
dently of its ion transport function, is also a critical struc-
tural protein for the formation and function of dendritic
spines in cortical neurons.42–44 Thus, effects correlated
solely with alterations in KCC2 expression levels cannot be
attributed directly to changes in Cl homeostasis. Genetic
deficits in KCC2, or its orthologs, result in increased excit-
ability in organisms as diverse as Caenorhabditis elegans,
Drosophila, and mice,45 but it is unclear to what extent this
is attributable to the structural versus transport roles of
KCC2. These observations suggest that elevating KCC2
protein levels by, for example, gene therapy might not be a
useful strategy. Specifically enhancing the transport activity
of KCC2 may be more relevant therapeutically.
Neuronal Cl extrusion mediated by KCC2 is prone to
fast activity-dependent modulation through posttransla-
tional modifications, including protein phosphorylation and
calpain-mediated cleavage.45 These nontranscriptional
regulatory pathways have significant consequences for the
efficacy of synaptic inhibition mediated by GABAARs, with
implications for neurologic diseases. Recent work has
demonstrated that KCC2-mediated Cl extrusion is rapidly
enhanced in response to neonatal seizures via recruitment of
the available intracellular KCC2 pool to the plasma mem-
brane.46 Such an intrinsic “antiepileptic” mechanism
suggests a putative therapeutic strategy whereby pharmaco-
logic kinetic activation of KCC2 might be utilized to help
suppress neonatal seizures.
A possible way to manipulate CCC activity is by target-
ing their upstream regulatory molecules. For example, N-
terminal threonine phosphorylation of NKCC1, required for
the activity of this transporter, is catalyzed by the WNK/
SPAK (with no lysine/Ste20-related proline alanine-rich
kinase) kinase cascade. This is in contrast to the situation
with KCC2, where activation of WNK kinases appears to
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have a suppressing effect on KCC2-mediated K-Cl cotrans-
port.47 Specific manipulation of such kinase pathways with
apparently opposing effects on KCC2 versus NKCC1 may
pose as a novel pharmacotherapeutic strategy.45 Here, the
fast membrane recycling of KCC248 could be exploited in
generating KCC2-activating drugs that would act to modu-
late KCC2 membrane insertion and functionality.
A recent high-throughput screening identified the com-
pound CLP257 and its carbamate prodrug derivative
CLP290 as KCC2-activating molecules.49 The parent com-
pound, CLP257, was reported to restore Cl extrusion in
adult neurons of the rat dorsal horn neurons incubated with
brain-derived neurotrophic factor and in an experimental
model of neuropathic pain. It remains unclear whether this
was due to effects on KCC2 membrane trafficking or on the
intrinsic transport kinetics of KCC2. Unlike the parent com-
pound CLP257, which has a plasma half-life of <15 min,
the prodrug CLP290 with a 5 h plasma half-life is more
likely to be utile in vivo. However, its pharmacodynamic
profile, including KCC2 specificity and mode of action, as
well as its brain availability remain to be assessed.
One should also note that intense activation of KCC2-
mediated K-Cl extrusion might lead to a proconvulsant
effect triggered by the consequent increase of K+ concen-
tration in the brain’s extracellular space.50,51 This is likely
to confound the use of KCC2 activators for anticonvulsant
purposes, as they might potentiate KCC2-mediated extra-
cellular K+ transients during ictal events. The KCC2-medi-
ated excitatory effect depends on the presence of neuronal
carbonic anhydrases,52 particularly on the isoform VII,
which is absent from neonatal pyramidal neurons in
rodents but shows a high level of expression in cortical
structures of the human neonate.15 This species-specific
difference may turn out to be of much significance when
extrapolating results and concepts from work on rodent
models of neonatal seizures, usually performed before
the time point (around postnatal day [P] 10) when
carbonic anhydrase expression commences in pyramidal
neurons.15
NKCC1
NKCC1 (encoded by SLC12A2) has been observed in vir-
tually all cell types studied, with highest expression on the
basolateral membranes of secretory epithelia, including the
kidney, and on the apical membrane of choroid plexus in the
brain. In epithelial cells NKCC1 contributes to the vectorial
transport of solute and water to drive fluid secretion.53 It is
also expressed in endocrine and neuroendocrine cells,54,55
vascular endothelial cells,53 including those in the blood–
brain barrier (BBB),56,57 as well as in neurons and glia.14
Given the wide expression of NKCC1, systemic administra-
tion of drugs that target it will influence a wide spectrum
of tissues throughout the organism. The participation of
NKCC1 in a variety of physiologic processes is well exem-
plified by the diverse phenotypes of NKCC1 KO mice,
including impaired gastrointestinal function, infertility, and
deafness arising from a sensory neuronal defect and dis-
rupted epithelial secretion of endolymph in the inner ear.14
Bumetanide as a Potential
Anticonvulsant Drug in
Neonates: Dosage and
Pharmacokinetics
Bumetanide is currently the only available compound
which, at low concentrations, inhibits NKCCs, without
significantly affecting the function of KCCs. A number
of studies have employed this drug in an attempt to sup-
press neonatal seizures in preclinical work on animal
models (Table 1). In addition, two clinical trials
(NCT01434225; NCT00830531) are being conducted on
the efficacy of bumetanide in the treatment of neonatal
seizures (see also Ref. 58). Therefore, we will devote
much attention to the pharmacokinetics and pharmacody-
namics of bumetanide.
Pharmacokinetic studies of bumetanide have been lar-
gely performed in the context of treatment for fluid over-
load in cardiopulmonary disease in adults and critically ill
term and preterm neonates.58,59 Plasma half-lives of bu-
metanide are in the range of 2–7 h in neonates of up to
4 weeks of age,59,60 while shorter (1–2 h) values are typi-
cally seen in infants and adults.59,61 Although the longer
half-life of bumetanide in neonates may be desirable from
the standpoint of brain targeting, it may also exaggerate
the undesired effects of bumetanide. As there is little dif-
ference in the bumetanide sensitivity between the ubiqui-
tously expressed NKCC1 and the main kidney isoform
NKCC2,62 targeting extrarenal NKCC1 with systemically
administered bumetanide stimulates diuresis and has the
potential side-effect of electrolyte abnormalities including
hypokalemic metabolic alkalosis.58,63
Bumetanide and furosemide (a non-selective inhibitor of
KCCs and NKCCs) are called “loop diuretics” because they
are actively concentrated by organic anion transporters in
the loop of Henle in the kidney’s thick ascending limb,64,65
and their diuretic action is mediated by inhibition of both
NKCC1 and the renal-specific NKCC2. In adult humans,
1 mg of orally administered bumetanide has a diuretic
potency equivalent to approximately 40 mg of furosemide
and this 1:40 dose equivalence ratio applies also to the intra-
venous (i.v.) administration route.66,67 The pediatric bumet-
anide doses (see Refs 59,68) appear to be based in part on
this ratio of diuresis induction efficacy, as for example sta-
ted in an influential paper by Sullivan et al.69: “The maxi-
mal dose [of bumetanide] (0.10 mg/kg) was based on the
usual pediatric dose of furosemide (1–2 mg/kg), reportedly
20–40-fold less potent than bumetanide in adults.” It
appears that the choice of using a rather low dose in most
rodent studies on bumetanide in neonatal seizures (see
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Table 1) has been guided by similar reasoning. In preclini-
cal work on rats, it has largely gone unnoticed that the half-
life of bumetanide in this species is very short: only about
10 min70,71 in adult and around 30 min35 in neonatal rats.
Accordingly, bumetanide concentrations, which are high
enough to exert pharmacologic actions outside the CNS in
the rat (as indicated by diuresis), can be achieved only at
high parenteral doses of ≥4 mg/kg.12,71 Likely due to less
rapid elimination, the maximal diuretic effect of bumeta-
nide in the adult human is reached at ~0.1 mg/kg12 and in
volume-overloaded critically ill infants at ~0.04 mg/kg.60
As a reference, the doses used in the multicenter clinical
trial NCT01434225 on bumetanide in neonatal seizures are
in the range of 0.05–0.3 mg/kg i.v., delivered four times at
12 h intervals. It is important to note that effects of bumeta-
nide in structures outside the CNS, such as the kidney, do
not imply that the drug would have any direct effects on
CNS neurons in rodents or humans.
Bumetanide as a Potential
Anticonvulsant Drug in
Neonates: Brain Availability
The question of whether bumetanide accumulates within
the BBB-protected brain parenchyma at NKCC1-inhibiting
concentrations after systemic administration has mostly
been addressed indirectly, by assuming that the anticonvul-
sant and disease-modifying effects of bumetanide (for
recent review, see Ref. 12) are indicative of the drug’s
actions in cortical and hippocampal neurons. However, such
actions might be indirect, reflecting drug effects on other
targets such as the endocrine system or the BBB, or effects
on total brain extracellular volume or systemic electrolyte
balance controlled by the kidney. Considerations based on
the pharmacokinetic properties of bumetanide, as well as
direct measurements of the drug’s concentration in brain
tissue, suggest that bumetanide is not likely to achieve phar-
macologically relevant levels in cortical structures with the
low doses used in most preclinical studies on neonatal
seizures (see below), and possibly in the ongoing clinical
trials referred to earlier on.
A crucial part of CNS drug development is the assess-
ment of the bioavailability of a candidate compound in the
brain; and the ability of a compound to penetrate the BBB is
often a major limiting factor.72 Only the unbound and non-
ionized (uncharged) form of bumetanide (or any other weak
acid) is able to diffuse across plasma membranes, including
those in the BBB. The degree of plasma protein binding
of bumetanide is high, at ~97–98% in rats and humans,
including human neonates.73–77 Furthermore, bumetanide
has a pKa = 3.6,
78 and thus, the free (unbound to protein)
plasma concentration (~2–3% of total) is ~99.98% ionized
at plasma pH of 7.4 (see equation). Hence, the concentration
of the free nonionized, BBB-permeable bumetanide species
is several orders of magnitude lower than the total plasma
concentration of the drug.
Bumenon-ionized ¼ Bumeionized  10ðpKaBumepHPlasmaÞ
Accordingly, a study on the ability of clinically estab-
lished drugs to penetrate the BBB reported the related loop
diuretic furosemide as unable to cross the BBB largely due
to its acidic pKa (<4).79
The bumetanide concentrations typically used in in vitro
studies for effective CNS inhibition of NKCC1 are in the
Table 1. Reported effects of bumetanide in in vivo animalmodels of neonatal seizures
Dose (mg/kg i.p.) Species Age Model Reported effect
Behavioral
analysis
EEG
analysis References
0.1–0.2 Rat P9-12 Kainate Anticonvulsanta No Yes Dzhala et al.19
0.15–0.3 Rat P10 Hypoxia No effect Yes Yes Cleary et al.35
0.2–2.5 Rat P7, P18 PTZ No effect Yes No Mares94
0.2–0.5 Rat P12 PTZ No effect Yes No
1 Rat P12 PTZ Anticonvulsant Yes No
2.5 Rat P12 PTZ Proconvulsant Yes No
0.5b Rat P11 Kindled ADT Anticonvulsant Yes Yes Mazarati et al.93
Rat P14, P21 Kindled ADT No effect Yes Yes
1.8 Rat P4-9 Sevoflurane Anticonvulsant No Yesc Edwards et al.90
1.8 Rat P5-9 Flurothyl No effect No Yes Minlebaev and
Khazipov91
0.1 (daily P11-P60)d Rat – Hyperthermia at P11 Decreased susceptibility
to PC-induced seizures at P60
Yes Yes Koyama et al.96
2 (daily P1-5) Mouse – Hyperthermia at P17 Proconvulsant Yes No Vargas et al.95
ADT, afterdischarge threshold; PC, pilocarpine; PTZ, pentylenetetrazole.
aAnticonvulsant effect deduced from EEG power.
bAdministered already during kindling.
cUnder anesthesia.
dBumetanide was administered after hyperthermia.
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range of ~2–10 lM.14 Given that bumetanide is likely to
inhibit NKCC1 from an extracellular site by binding within
the translocation cavity in the third transmembrane helix,80
its high ionization is not a problem for use in vitro, or for
acting on targets in vivo that are not protected by the BBB
(e.g., NKCC1 expressed on the luminal membrane of the
cerebral vascular endothelium). However, because the bu-
metanide fraction unbound to plasma protein is only ~2–3%
of total, substantially higher serum concentrations are
needed to achieve a transient half-maximal inhibition of
NKCC1 in vivo compared to in vitro conditions, where
plasma protein binding and the BBB do not limit neuronal
target access. Such concentrations are reached only tran-
siently in the blood, even after very high bumetanide doses,
which are two orders of magnitude higher than those used in
the neonatal and pediatric patient. Also, when evaluating
the in vivo bumetanide dose-effect data, one should note
that a given dose of bumetanide applied i.v., will, of course,
lead to a higher concentration in brain capillaries than when
applied via the intraperitoneal (i.p.) route.
In addition to the high degree of protein-binding and ioni-
zation of bumetanide in the blood, a number of its pharma-
cokinetic parameters indicate poor BBB penetration. The
nonionized form of bumetanide is relatively lipophilic (log
P ~3)62,81,82; however, the experimentally determined distri-
bution coefficient (log D7.4), which takes into account ioni-
zation at pH 7.4, is very low (between 0.11 and 0.14).82,83
The parallel artificial membrane permeability assay
(PAMPA) score of bumetanide at pH 7.4 is also low (0.3).82
Accordingly, following i.v. administration of14 C-labeled
bumetanide to healthy human volunteers, accumulation into
red blood cells could not be detected, despite a marked
diuretic effect.61 Another key factor restricting the entry of
compounds into the CNS is a drug polar surface area (PSA)
value higher than 80 A2.72,84 The PSA of bumetanide is
~123 A2.81,82 For comparison, the log D7.4 of the commonly
used CNS-acting AED phenytoin is 2.26, the PAMPA score
at pH 7.4 is 5.1, and it has a PSA of 65 A2.82 Indeed, 3H-
labeled bumetanide has been reported to cross the rat BBB
at a rate 100-fold slower than that predicted by passive dif-
fusion.83 There is also some indication that bumetanide may
be subject to active efflux transport from the brain via trans-
port mechanisms of the BBB.85,86
Direct data on bumetanide brain accumulation obtained
using liquid chromatography are in full accord with the
poor BBB permeability predicted by the above physico-
chemical parameters. In neonatal rats, extremely low brain/
plasma ratios with peak values of only 0.0036–0.0056 were
observed during the first hour after i.p. administration of
bumetanide at 0.15–0.3 mg/kg.35 Thus, only <1% of the
total bumetanide in the plasma penetrated into the brain.
Indeed, total brain concentrations achieved with this dose
in the neonatal brain were only ~1 ng/g brain tissue,35
which, assuming an average brain density of ~1 g/ml, is
equal to a negligible level of ~3 nM. Notably, in neonatal
rats which had experienced hypoxia-induced seizures, the
brain concentrations achieved were within the same range
(Fig. 3).35 Such total brain concentrations of bumetanide
are orders of magnitude lower than the ~200–300 nM half-
maximal inhibitory concentration (IC50) of bumetanide for
NKCC1.53,62
In order to achieve pharmacologically relevant concen-
trations of bumetanide in the CNS, systemic doses much
higher than those above are needed. Similarly to neonates,
a very low brain/plasma concentration ratio of 0.0068 was
measured for bumetanide 30 min after an i.p. dose of
0.3 mg/kg in adult rats.87 Only after increasing the system-
ically administered dose of bumetanide by nearly two
orders of magnitude, could brain concentrations in the
range of the half maximal inhibition constant of NKCC1
be briefly reached. Bumetanide at 10 mg/kg administered
i.v. resulted in concentrations of ~0.3 lM at 15 min and
~0.2 lM at 30 min in hippocampi of adult rats.71 With a
higher dose of 15 mg/kg (given i.p.) total bumetanide con-
centrations in the hippocampus ranged between 0.3 and 0.7
lM 30-60 min after the injection, with similar concentra-
tion values detected in the amygdala and the piriform cor-
tex.70 In mice, a species with a longer bumetanide plasma
half-life of ~50 min, the lower dose 10 mg/kg (i.v.)
yielded only marginally higher total brain levels of
0.75 lM at 30 min.71 In nephrectomized dogs, where the
renal clearance of bumetanide does not limit its half-life,
i.v. infusion of bumetanide (50 mg/kg) resulted only in
submicromolar (0.7 lM) cerebrospinal fluid bumetanide
concentrations, despite reaching extremely high total
plasma concentrations (close to 300 lM) for several
hours.88
T€opfer et al.71 examined the use of the cytochrome P450
inhibitor piperonyl butoxide with the aim of prolonging the
elimination half-life of bumetanide and thus increasing the
translational value of results based on rodent models. Using
this approach in adult animals, the authors were able to
increase the maximal hippocampal bumetanide levels (with
a drug dose of 10 mg/kg i.v.) from 0.2–0.3 lM to 0.6 lM
in rats and from 0.7–0.8 lM to 2 lM in mice. However, this
modest increase did not lead to an anticonvulsant effect in
the seizure models tested.
In light of bumetanide’s poor BBB penetration, its effects
on the CNS have often been a priori attributed in part to
enhanced brain accumulation as a result of a seizure-
induced breakdown of the BBB. The only study to investi-
gate this in neonatal rats did not show any significant
increase in brain accumulation of bumetanide (given at 0.2–
0.3 mg/kg i.p.) following hypoxia-induced seizures.35 In
line with this, after a relatively high dose of bumetanide
(10 mg/kg i.v.), no difference in total hippocampal bumeta-
nide levels were reported between nonkindled and fully kin-
dled adult rats,71 or in total brain bumetanide levels between
adult mice 24 h after pilocarpine status epilepticus or sham
treatment.89
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In summary, all the above data argue against the view that
systemic administration of bumetanide at the low concen-
trations used in the majority of studies reporting anticonvul-
sant effects in rodent models of neonatal seizures (see
Table 1) would achieve physiologically relevant levels in
brain regions protected by the BBB.
Preclinical Observations with
Bumetanide as an Anticonvulsant
in Neonates
The preclinical in vitro and in vivo data on actions of
NKCC1 inhibitors in seizure models have been recently
reviewed in detail.12 With regard to neonatal seizures, no
data exist for furosemide, whereas a number of studies have
examined the anticonvulsant potential of bumetanide in
vivo (Table 1).
Only a few studies have assessed the effect of bumetanide
on electrographic seizures in vivo. Bumetanide had a sup-
pressing effect on epileptiform activity induced by sevoflu-
rane,90 but no effect was seen using a similar dose of
bumetanide (1.8 mg/kg i.p.) in the flurothyl model.91 In the
former study,90 bumetanide was administered 15 min
before sevoflurane inhalation, whereas in the latter bumeta-
nide was given 60 min before flurothyl,91 which may not be
a trivial difference given the 30 min half-life of bumetanide
in rats of this age (see above). In a paper on kainate-induced
seizures, which generated much of the interest in bumeta-
nide as an anticonvulsant in neonates, Dzhala et al.19
reported that bumetanide at an i.p. dose of 0.1–0.2 mg/kg,
given 10 min after the kainate injection, led to a reduction
in the power of EEG activity when compared to control ani-
mals. But, as pointed out by Vanhatalo et al.,92 mere
changes in the spectral power of ictal EEG do not reliably
define an anticonvulsant effect, especially in view of the
low number of bumetanide-injected animals (n = 3) that
were subject to EEG analysis in the study by Dzhala et al. A
recent investigation on hypoxia-induced seizures35 failed to
induce significant changes in EEG spectral power in rats of
similar age and exposed to similar bumetanide concentra-
tions as in the study by Dzhala et al. Using rapid hippocam-
pal kindling, Mazarati et al. reported that bumetanide at
0.5 mg/kg, but not at 0.2 mg/kg, given during electrical
kindling (see Ref. 12), increased afterdischarge threshold
and shortened afterdischarge duration in P11 but not in P14
or P21 rats.93 In the P11 group, bumetanide at 0.5 mg/kg
doubled the number of stimulations required to evoke the
first full motor seizure as well as reduced the total number
of motor seizures.93
Regarding the effects of bumetanide on behavioral sei-
zures in neonatal rats, a modest reduction in acute
hypoxia-induced seizures was observed in P10 rats using
video-EEG after a bumetanide dose of 0.3 mg/kg given
i.p. 15 min before seizure onset, but not after a dose of
0.15 or 0.5 mg/kg.35 In the pentylenetetrazole seizure
model, bumetanide at 1 mg/kg i.p. had an anticonvulsant
effect in rat pups at 12 days of age, but not at P7 or P18.94
Increasing the dose to 2.5 mg/kg was found to be procon-
vulsant but, again, only in the P12 group.94 Daily i.p.
administration of 2 mg/kg of bumetanide during the first
5 days of life potentiated febrile seizures experimentally
induced in the third postnatal week.95 In contrast, a daily
low dose (0.1 mg/kg, i.p.) of bumetanide administered to
rats after experimental febrile seizures at P11 decreased
the susceptibility to pilocarpine-induced seizures at P60.96
Taken together, the preclinical in vivo evidence in support
of bumetanide alone as an efficient neonatal anticonvul-
sant is not robust.
The use of bumetanide to enhance the effects of pheno-
barbital in neonatal seizure suppression was proposed by
Staley et al.97 The underlying idea is elegant: blocking first
the depolarizing driving force of GABA currents and Cl
accumulation using bumetanide, and thereafter increasing
the GABA-induced conductance using phenobarbital or a
Figure 3.
Total bumetanide concentrations in
brain tissue of naive and hypoxia-
exposed neonatal rats. Bumetanide
concentrations of ~2–3 nM (100-fold
lower than the half-maximal NKCC1
inhibitory concentration) are reached
in brain tissue of 10-day-old rats
following intraperitoneal
administration at 0.15–0.3 mg/kg.
Notably, brain concentrations of
bumetanide are similar in naive
control animals and those which
experienced hypoxia-induced
seizures. Error bars indicate SEM.
Data in the diagram derived from
Cleary et al.35
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benzodiazepine is expected to lead to a potent anticonvul-
sant effect. Also, as pointed out by Ben-Ari et al., the earlier
administration of bumetanide may help to ameliorate the
eventual down-regulation of KCC2 and possible seizure
aggravation,32 which take place after an initial functional
up-regulation of KCC2 by neonatal seizures.46 In clinical
practice, where GABAAR enhancers must be used as first-
line drugs, it is not possible to begin drug administration
with bumetanide. Recent work in vivo using a rat model of
hypoxia-induced neonatal seizures reported lower seizure
burden obtained with a combination of phenobarbital and
bumetanide, versus phenobarbital or bumetanide (0.15–
0.3 mg/kg i.p.) alone.35 Interestingly, reduced cerebral
damage and improved sensorimotor functions have been
reported when a high dose of bumetanide (10 mg/kg i.p.)
was used in conjunction with phenobarbital and hypother-
mia in a neonatal rat model of cerebral hypoxia-ischemia.98
However, the effects on seizures were not assessed in this
study. In view of the already poor pharmacokinetic proper-
ties of bumetanide it is important to note that, as seen in rats,
phenobarbital may increase the metabolic clearance of
bumetanide.99
In sum, considering the fact that clinical trials are ongo-
ing, the number of studies on bumetanide actions on sei-
zures in vivo is surprisingly small and no data are available
on large-animal models.
Neuroprotective Effects of
Bumetanide Acting on BBB-
Located NKCC1
The BBB endothelium luminal (blood-facing) Na+ and
Cl transporter systems generate up to a third of the brain
interstitial fluid volume.57 During the early stages follow-
ing ischemic injury, a common consequence of birth
asphyxia, up-regulation of channels and transporters in the
BBB facilitates net uptake of cations and water from the
blood into the brain interstitial space across the yet intact
BBB. This results in ionic edema and swelling of the brain
parenchyma.56 NKCC1, highly expressed in the BBB and
choroid plexus,57,100 is phosphorylated and functionally
stimulated under ischemic conditions, thereby facilitating
ionic edema in the early stages of brain ischemia.56 It is
notable that cerebral edema and accompanying brain damage
are strongly attenuated in NKCC1 KO mice.101 O’Donnell
et al.57 reported that high doses of bumetanide in the range
of 7–30 mg/kg (i.v.) ameliorate edema induced by middle
cerebral artery occlusion without reperfusion in adult rats.
The authors concluded that this effect is unlikely to involve
inhibition of NKCC1 of the brain parenchyma but rather
that of endothelial cells, due to the poor ability of bumeta-
nide to permeate the BBB.57 Work by others indicates that
bumetanide administered at a high dose (15 mg/kg, i.v.),
prior to BBB breakdown, attenuates brain edema induced
by traumatic brain injury in adult rats.102 Due to its luminal
expression in BBB endothelial cells,57 NKCC1 is directly
exposed to systemically administered bumetanide. There-
fore, it is possible that bumetanide prevents BBB break-
down by inhibiting endothelial NKCC1 activity. Thus, a
relevant question is whether targeting BBB-located
NKCC1 with bumetanide may suppress hypoxia-ischemia–
induced seizures by preventing the escalation of ionic
edema into vasogenic edema and BBB disruption in the as-
phyxic neonate.
NKCC1 in the Hypothalamic-
Pituitary-Adrenal Axis:
A Possible Site of the
Anticonvulsant Actions of
Bumetanide?
Mounting evidence indicates that the mechanisms
underlying seizure generation and stress are closely
linked.103,104 Intriguingly, bumetanide (and furosemide)
has been shown to exert anxiolytic effects.105 The media-
tor of the body’s stress response, the hypothalamic-pitui-
tary-adrenal (HPA) axis undergoes robust activation in
response to neonatal hypoxia-ischemia.106,107 The major
mediator of the hormonal and behavioral responses to
stress is the neuropeptide corticotropin releasing hormone
(CRH). CRH is an excitatory neuropeptide that is tightly
coupled to seizure susceptibility in both the adult and neo-
natal brain, with the latter apparently more sensitive to
CRH as exemplified by the fact that the lowest seizure
triggering CRH concentrations are two orders of magni-
tude lower in neonatal rats.103 Significantly higher CRH
concentrations have been reported in umbilical cord
plasma of asphyxiated human neonates than in those that
had experienced uncomplicated birth.106 Recent work has
demonstrated that CRH application triggers N-methyl-D-
aspartate receptor/calpain–dependent downstream mecha-
nisms108 that have been also implicated in the activity-
dependent down-regulation of KCC2.109
The release of CRH from neurosecretory nerve terminals
of periventricular (PVN) neurons in the median eminence is
tightly regulated by GABAergic inhibitory input onto PVN
neurons, which limits the release of neuropeptides.104
Recent work by Maguire et al.110,111 on adult rodents dem-
onstrated rapid down-regulation of KCC2 paralleled by up-
regulation of NKCC1 and emergence of excitatory GABA
action on CRH-releasing PVN neurons by acute stress and
seizures. Presynaptic nerve terminals are known to express
both GABAARs and NKCC1 but not KCC2.
14 This high-
lights the activity of NKCC1 in the neurosecretory terminals
as an important determinant of the nature of GABAergic
control over CRH release. Such a role may be relevant,
especially in neurons in which KCC2 has been down-
regulated by seizures. The median eminence, where the
neurosecretory terminals of PVN neurons are located, is one
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of the circumventricular organs of the brain, a group of dis-
crete brain regions characterized by a “leaky” BBB with
fenestrated endothelial cells lacking tight junctions.
Because of this, neuroendocrine cells in the PVN, including
CRH releasing neurons, are likely to be directly exposed to
systemically administered bumetanide. An interesting
hypothesis is that bumetanide might suppress seizures by
inhibiting NKCC1 in the PVN neurons, thus limiting CRH
release and HPA-axis activation.104 It is also important to
note that dehydration and hypovolemia, which are likely to
be associated with the renal effects of bumetanide, may
have a suppressing action on transcription of CRH.112 Of
interest, bumetanide administered at low concentrations
(0.2 mg/kg i.p.) previously shown to result in brain levels
that are two orders of magnitude lower than the half maxi-
mal inhibition constant for NKCC1 inhibition (see above),
was demonstrated to block seizure-induced activation of the
HPA axis and decrease susceptibility to future seizures
in adult mice.111 An important next step is to investi-
gate whether bumetanide attenuates hypoxia-ischemia- and
seizure-induced activation of the HPA axis in neonatal
animals.
Concluding Remarks
The work reviewed presently focuses on KCC2 and
NKCC1 as potential drug targets in the treatment of neona-
tal seizures. Testing the hypothesis that transient pharmaco-
logic activation of KCC2 would ameliorate neonatal
seizures directly and/or increase the efficacy of GABA-
enhancing AEDs, such as phenobarbital, is currently limited
by the lack of well-characterized KCC2 activators.
Although the first steps have recently been taken in this
direction,49 the drugs’ specificity to KCC2 should be con-
firmed. Notably, the putative KCC2 activators should not
interfere with the role of KCC2 in promoting the maturation
of dendritic spines and other neurodevelopmental processes
(see above).
The major problems when using bumetanide to block
NKCC1 are related to its poor pharmacokinetic properties,
which largely limit the inhibition of NKCC1 in BBB-pro-
tected brain areas, as well as its side effects including but
not limited to diuresis, hypokalemic alkalosis, and hearing
loss;58,63 and the latter is likely to be potentiated by coad-
ministration of antibiotics (such as aminoglycosides).68
Notably, a systemic alkalosis is likely to be harmful given
that a very small pH increase (0.2 units or even less) in the
neonate brain may trigger seizures.113
The above considerations related to the poor brain avail-
ability of bumetanide do not exclude inhibition of NKCC1
in hippocampal and neocortical neurons as another poten-
tially useful approach in neonatal seizures, as exemplified
by encouraging work on a combination of bumetanide with
phenobarbital in an in vitro model of neonatal seizures.97
However, testing this more reliably in vivo requires specific
NKCC1 inhibitors with improved CNS availability. Here, a
strategy based on prodrugs where bumetanide is initially
neutralized by an ester bond to facilitate CNS availability,
may turn out to be useful.89
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